Radio and PodcastLive Radio & Podcasts

Search Radio and Podcast

Podcasts›FDA Drug Safety Podcasts›FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)

Science & Medicine

FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)

FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research

Dec 16, 20224:00Science & Medicine

Related Episodes

Continue listening to more episodes from FDA Drug Safety Podcasts.

Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis

Jan 2, 2025 - 5:00

Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to tr...

FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause

Sep 20, 2024 - 3:30

Listen to an audio podcast of the September 12th, 2024 FDA Drug Safety Communication on rare occurrence o...

FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab)

Feb 6, 2024 - 4:00

Listen to FDA Drug Safety Podcast titled, FDA adds Boxed Warning for increased risk of severe hypocalcemi...

Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity

Jan 26, 2024 - 3:30

Listen to FDA Drug Safety Podcast, FDA's preliminary evaluation has not found evidence that use of GLP-1...

FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan)

Dec 8, 2023 - 5:05

Listen to an audio podcast of the November 28, 2023, FDA Drug Safety Communication, FDA warns of rare but...